EGF-R POSITIVE NON-SMALL CELL LUNG CANCER
Clinical trials for EGF-R POSITIVE NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EGF-R POSITIVE NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EGF-R POSITIVE NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare lung cancer mutations: dacomitinib trial underway
Disease control OngoingThis phase 2 trial tests the drug dacomitinib in 30 people with advanced non-small cell lung cancer that has uncommon EGFR mutations. Participants take a daily pill until their disease worsens or side effects become too much. The main goal is to see how many patients' tumors shri…
Matched conditions: EGF-R POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 23, 2026 23:50 UTC
-
New pill targets tough cancers in early trial
Disease control OngoingThis early-stage trial is testing an oral drug called silevertinib (BDTX-1535) in about 200 adults with advanced non-small cell lung cancer or glioblastoma that have certain EGFR mutations. The study has two parts: first finding a safe dose, then checking if the drug shrinks tumo…
Matched conditions: EGF-R POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Black Diamond Therapeutics, Inc. • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC